Breast cancer treatment from thiazolidinedione derivatives

CONTEXT 

Treatments against breast cancer occur certain limits: innate or acquired resistance, absence of targeted therapy for certain tumors.
Although the anticancer properties of thiazolidinediones have been demonstrated in vitro and in vivo (phase II clinical study), some of them cannot be used due to excessive hepatotoxicity.

DESCRIPTION 

The invention consists in the development of a very stable troglitazone derivative, 4 times less toxic on primary hepatocyte culture (80% viability vs. 23%) and whose in vitro antiproliferative activity is 10 times higher than troglitazone. In vivo preclinical tests on xenografted mice are ongoing.

COMPETITIVE ADVANTAGES

• Increased efficacy against breast cancers even resistant to treatments and triple-negative cancers for which there is no targeted therapy
• Reduced side effects: 70% less liver toxicity compared to troglitazone

MARKETS & APPLICATIONS 

Pharmaceutical: Anti-cancer treatment

DEVELOPMENT STAGE 

TRL 4: in vitro toxicity and anticancer activity validation

INTELLECTUAL PROPERTY

Patent registered in France on January 26th, 2012 (FR2986231) and extended in Europe (October 2016 ; EP2838899) and USA (December 2016 ; US2014364465)

TARGET PARTNERSHIP
Patent licensing

CONTACT 

Ludmila Monteiro

Business Developer

+33 (0)6 31 10 21 21

ludmila.monteiro@sayens.fr